Generic Name and Formulations:
Methsuximide 300mg; caps.
Indications for CELONTIN:
Absence (petit mal) seizures refractory to other drugs.
Adults and Children:
Individualize. Initially 300mg once daily for the 1st week; may increase at weekly intervals by 300mg/day for 3 weeks based on response; max 1.2g daily. May be administered with other anticonvulsants.
Monitor blood counts periodically, esp. if signs/symptoms of infection develop. Hepatic or renal impairment; monitor urine and liver function tests. Monitor for new or worsening depression, suicidal thoughts and/or unusual changes in behavior; withdraw gradually if occur. May increase frequency of grand mal seizures when used alone in mixed seizure type. Avoid abrupt cessation. Pregnancy.
May potentiate phenytoin, phenobarbital; monitor periodically.
Nausea, vomiting, diarrhea, weight loss, abdominal pain, constipation, blood dyscrasias, confusion, depression, drowsiness, ataxia, dizziness, rash, urticaria, hyperemia, proteinuria, hematuria; rare: SLE, suicidal ideation, psychosis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age